Lactobacillus Johnsonii in Children and Adolescents With T1D

Phase 2

Recruiting

• Conditions: Type 1 Diabetes (T1D)
• Interventions: Drug: L. johnsonii Probiotic; Drug: Placebo Capsule

• Registration Number: NCT03961854
• Lead Sponsor: University of Florida

Brief Summary

While genetics demonstrated a major risk factor for the development of type 1 diabetes (T1D), microbiota dysbiosis has been suggested as an elicitor in immunological tolerance and of beta cell autoimmunity. The probiotic Lactobacillus johnsonii N6.2 may prevent or restore the gut flora and show systemic impacts and adaptive immunity in the T1D population thereby preserving beta cell function.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2019-05-22
• Study First Submitted QC: 2019-05-22
• Study First Posted: 2019-05-23
• Study Start: 2019-10-10
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-09
• Last Update Posted: 2024-08-12
• Primary Completion: 2026-03-01
• Study Completion: 2026-03-11

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 57

Inclusion Criteria

• have confirmed T1D by physician diagnosis
• have normal values at screening for complete blood count (CBC) and complete metabolic profiles (with the exception of fasting glucose and HbA1c)
• are able to swallow a capsule
• are willing to complete weekly online questionnaires
• are willing to consume a probiotic
• are willing to provide stool samples throughout the study
• are willing to provide blood samples throughout the study
• are willing to take three stimulated C-peptide tests
• are able to access a computer with Internet throughout the study

Read More

Exclusion Criteria

• being treated for any diseases or illnesses such as gastrointestinal disease (gastric ulcers, Crohn's disease, ulcerative colitis, etc.)
• being treated for chronic kidney disease
• have had or are currently being treated for other immune-compromising diseases or conditions (HIV, AIDS, hepatitis, cancer, leukemia, organ transplant, Lupus, DiGeorge syndrome, selective deficiency of IgA, Bruton's disease etc.)
• have an underlying structural heart disease
• currently live with an immunocompromised person
• are currently taking medications for constipation and/or diarrhea
• have taken antibiotics within the past 2 weeks prior to randomization
• are currently taking a probiotic supplement and are unwilling to discontinue it a minimum of 2 weeks prior to the study start
• are a current smoker
• are currently pregnant or lactating or a female who plans to become pregnant in the next 6 months
• have a known allergy to milk or milk protein.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Probiotic Group	L. johnsonii Probiotic	The probiotic group will receive a daily capsule with Lactobacillus johnsonii N6.2 1x109 CFUs. Participants will consume one capsule (treatment or placebo) daily for 24 weeks.
Placebo Group	Placebo Capsule	The placebo group will receive a capsule daily with dried skim milk (vehicle of the probiotic). Participants will consume one capsule (treatment or placebo) daily for 24 weeks.

Primary Outcome Measures

Name	Time	Method
Adverse Event and/or Serious Adverse Event	24 weeks	Adverse Event and/or Serious Adverse Event will be recorded daily by parents and notified to investigator within 24 hrs., in particular gastro-intestinal symptoms, fever and rashes.
Tolerance will be evaluated according to their responses on weekly questionnaires	52 weeks	The weekly questionnaire will ask participants to respond to questions regarding their gastrointestinal health (bowel movement frequency, gastrointestinal and other symptoms (i.e., constipation, diarrhea, stomach pain) and general wellness (if you consumed an antibiotic, visited a doctor, etc.). The questionnaires follow a scale from 1-7, 1 = No discomfort at all, 7 = Very severe discomfort.
Safety will be evaluated according to complete blood count (CBC) and complete comprehensive metabolic panel (CMP)	52 weeks	CBC and CMP will be evaluated at four different time points during study: 1st measure will be at screening visit and before starting intervention (visit 1/week -4, baseline period), 2nd measure will be after 12 weeks after starting intervention (visit 2/ week 12), 3rd measure will be after the 24 weeks of intervention (visit 3/ week 24) and the 4th measure will be 24 weeks later, end of washout period (visit 4/week 48). Values should be within the normal values except for glucose.

Trial Locations

Locations (1)

UF Clinical Research Center; 🇺🇸 Gainesville, Florida, United States